A study from University of Cambridge and Warwick Clinical Trials has shown that Herceptin treatment length could be halved.
Geisinger Health System CEO, Dr. David Feinberg reveals health system’s pioneering precision health efforts will be recommended to every patient.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
Thermo Fisher Scientific has signed agreements with Takeda Pharmaceuticals and Daiichi Sanyo that will enable the Japanese firms to leverage Thermo Fisher’s FDA approved Oncomine Dx Target Test for their clinical trials and drug development programs.
Gilead Sciences will partner with Google Parent Alphabet’s Verily Life Sciences over the next three years, applying Verily’s Immunoscape platform to better understand the immunological basis of three common diseases.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
A new cancer cell-based assay could help doctors diagnose cancer, better monitor the disease, and take a step closer to customised treatment for individual patients.
Even though the $550 yellow pills sold as Korlym have a controversial origin as the abortion pill, Leslie Edwin said they “gave me life.”
Scientist Andrew Feinberg calls for more integration between two fields of DNA-based research: genetics and epigenetics.